CRANBURY, N.J., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced that enrollment is complete in the first Phase 3 global registration study (Study 011) of migalastat HCl for Fabry disease. Based on the timing of this milestone, Amicus and its collaborator GlaxoSmithKline (GSK) anticipate Study 011 results in the third quarter of 2012.
